… drug persistence rate of UST [ustekinumab], validating its role as a possible treatment … , in the Journal of Clinical Medicine. LIMITATIONS: This study was retrospective … on speakers bureaus for various pharmaceutical companies. This article was created …

… Taiwan; 3Institute of Medicine, College of Medicine, Chung Shan Medical University, Taichung, Taiwan … with psoriasis have a higher risk of AAVs development. Treatment with … 12/23 p40 inhibitor (ustekinumab). Statistical Analysis Statistical analyses were …

… disease model. The drug treatment group was given medication by gavage for 7 … promote the development of inflammation. Ustekinumab can reduce the expression of … treatment of terminal ileitis in Crohn’s disease: the LIR!C trial …

… 17A for the treatment of pustular psoriasis: a comprehensive … psoriasis: a randomized, double-blind, placebo-controlled Phase 3 trial … Vunakizumab: first Approval. Drugs. 2024;84(11):1481– … treated with ixekizumab and ustekinumab. Dermatol Pract Conceptual. …

… biotech company specializing in the development and manufacture of biosimilar medicines … men receiving treatment for prostate cancer … ) and Stelara® (ustekinumab) are already approved and … Corporation (Canada), Yangtze River Pharmaceutical (Group) Co., Ltd …

… medicinal product. It is highly similar to the reference product Stelara (ustekinumab … psoriasis Usgena is indicated for the treatment of moderate to severe plaque psoriasis … -biological disease-modifying anti-rheumatic drug (DMARD) therapy has been …

… positive opinions for nine biosimilar medicines: Acvybra (denosumab), Denosumab Intas … (ustekinumab), for the treatment of Crohn’s disease, plaque psoriasis and paediatric plaque psoriasis … committee also recommended a new pharmaceutical form and a new …

… targeted oral peptide treatment has the potential … ustekinumab) in the Phase III ICONIC-ASCEND trial in patients with plaque psoriasis … Drug Administration (FDA) for icotrokinra in moderate to severe plaque psoriasis … The Clinical Trials Arena Excellence Awards …

… data comes after a New Drug Application (NDA) was … -ADVANCE 1 and 2 trials highlighted the superiority of … an oral psoriasis therapy, icotrokinra, with an injectable biologic, ustekinumab.2 … a new standard of treatment for psoriasis patients with a once …

… ADVANCE 1 and 2 trials confirmed superiority over deucravacitinib, … superiority of icotrokinra against ustekinumab, an IL-12… Johnson & Johnson Innovative Medicine, in the release. “A … the psoriasis treatment landscape. With the ICONIC-ASCEND trial now …